ArticleScience advances2025
Hepatic hypertension on-a-chip identifies GPR116 as a hydrostatic pressure mechanosensor to regulate vascular injury in cirrhosis.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Use of Antihistamine Drugs in Colitis: A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- From bench to bedside: Molecular mechanisms, diagnostic tools, and therapeutic strategies in liver fibrosis.Liver research (Beijing, China) · 2026Review
- Simvastatin in liver diseases: therapeutic value and research advances.Clinical and experimental medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cirrhosis-associated portal hypertension drives vascular injury, yet the pathogenesis mediated by abnormal hydrostatic pressure (HP) remains unclear due to the absence of in vitro models replicating the cirrhotic perivascular mechanical microenvironment. Here, we developed 2D static and 3D dynamic "hepatic hypertension on-a-chip" (HH chip) systems replicating cirrhotic hemodynamics and matrix properties. The HH chip realized integration and decoupled regulation of HP, shear stress, and matrix stiffness. Liver sinusoidal endothelial cells (LSECs) exhibited HP-induced damage exclusively on stiff matrices, recapitulating cirrhotic degeneration phenotypes and genotypes. Using the HH chip, we identified GPR116 as the key HP mechanosensor in LSECs and delineated its downstream mechanotransduction pathway driving cellular injury. Genetic silencing of GPR116 protected endothelial cells from HP-induced damage both in vitro and in cirrhotic murine models. Cell- and gene-based therapies targeting GPR116 significantly attenuated cirrhosis progression. The HH chip can accelerate pathological investigation, target identification, and therapeutic development for hypertension-associated diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.